Compare Megapower Makmur Tbk. (MPOW) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Megapower Makmur Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Megapower Makmur Tbk. trades at Rp113 (market cap 92.32B, 2.98M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Megapower Makmur Tbk. and Organon Pharma Indonesia Tbk. are close in size by market cap. Which is the better fit depends on your goals.
| MPOW | SCPI | |
|---|---|---|
Market Cap | 92.32B | 104.4B |
Volume | 2.98M | — |
Lot | 29.77K | — |
Turnover | 331.73M | — |
Average Price | 111.41 | — |
Value | 331.73M | — |
Indicative Equilibrium Price | 113 | — |
Indicative Equilibrium Volume | 789 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Megapower Makmur Tbk.
PT Megapower Makmur Tbk (the Company) was established based on notarial deed No. 05 dated August 1, 2007 and amended with deed No. 160 dated September 19, 2007, both made in front of Ms. Rose Takarina, S.H., notary in Jakarta. In 2010, Megapower Makmur had acquired by Bina Puri Holdings Bhd and start investing through Power plant in one of the Indonesia shortage of electricity area. In 2012, Megapower Makmur totally has become an Indonesia IPP (Independent Power Producer) Company. Megapower Makmur currently is a subsidiary of Bina Puri Holdings Bhd, a public company listed on the main board of Bursa Malaysia Berhad, with 40 years of work experience in the field of civil construction and the building of both local and international.
Read more on MPOW →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
